Qiagen (NYSE:QGEN) Announces Earnings Results

Qiagen (NYSE:QGEN) announced its quarterly earnings results on Wednesday. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.02, Zacks reports. The firm had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a return on equity of 14.24% and a net margin of 19.49%.The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.60 EPS. Qiagen updated its FY 2026 guidance to 2.430- EPS.

Qiagen Stock Up 1.3%

Shares of Qiagen stock traded up $0.56 on Friday, hitting $42.29. 1,385,288 shares of the company’s stock traded hands, compared to its average volume of 2,434,545. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. The stock has a market cap of $8.71 billion, a P/E ratio of 21.68, a PEG ratio of 4.19 and a beta of 0.63. The firm’s 50-day moving average is $39.32 and its 200 day moving average is $41.69.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were paid a dividend of $0.35 per share. This is an increase from Qiagen’s previous annual dividend of $0.26. The ex-dividend date was Tuesday, July 7th. This represents a dividend yield of 90.0%. Qiagen’s dividend payout ratio (DPR) is currently 18.32%.

Institutional Trading of Qiagen

Several institutional investors have recently added to or reduced their stakes in QGEN. O Shaughnessy Asset Management LLC purchased a new position in Qiagen during the 4th quarter worth approximately $242,000. Quadrant Capital Group LLC boosted its position in shares of Qiagen by 26.5% in the third quarter. Quadrant Capital Group LLC now owns 5,273 shares of the company’s stock worth $236,000 after buying an additional 1,105 shares during the period. Osaic Holdings Inc. boosted its position in shares of Qiagen by 101.4% in the second quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock worth $185,000 after buying an additional 1,951 shares during the period. Pitcairn Co. purchased a new position in shares of Qiagen during the second quarter valued at $208,000. Finally, Evergreen Capital Management LLC acquired a new position in Qiagen during the second quarter valued at $246,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on QGEN shares. Citigroup reiterated a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. Zacks Research raised shares of Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. raised their price target on shares of Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday. Robert W. Baird set a $43.00 price objective on shares of Qiagen and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Finally, Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $43.34.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.